Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-06-16
2010-11-02
Saunders, David A (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S152100, C424S172100, C424S177100, C530S390500, C530S413000
Reexamination Certificate
active
07825223
ABSTRACT:
The present application provides methods of purifying Aβ binding proteins having a Fc region, for example, anti-Aβ antibodies or antibody fusions, by adsorbing the Aβ binding protein to a Fc binding agent, such as, for example, Protein A or Protein G, followed by a wash with a divalent cation salt buffer to remove impurities and subsequent recovery of the adsorbed Aβ binding protein. The present application also features methods of eluting the purified Aβ binding protein as well as the incorporation of the methods within a purification train. Kits comprising components for carrying out the methods and instructions for use are also provided.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4851341 (1989-07-01), Hopp et al.
patent: 5112952 (1992-05-01), Mallia et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5225539 (1993-07-01), Winter
patent: 5336603 (1994-08-01), Capon et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5786180 (1998-07-01), Konig et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6420113 (2002-07-01), Buechler et al.
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6750324 (2004-06-01), Schenk et al.
patent: 6761888 (2004-07-01), Schenk
patent: 6787138 (2004-09-01), Schenk
patent: 6787139 (2004-09-01), Schenk
patent: 6787140 (2004-09-01), Schenk
patent: 6787143 (2004-09-01), Schenk
patent: 6787144 (2004-09-01), Schenk
patent: 6787523 (2004-09-01), Schenk
patent: 6787637 (2004-09-01), Schenk et al.
patent: 6808712 (2004-10-01), Schenk
patent: 6818218 (2004-11-01), Schenk
patent: 6866849 (2005-03-01), Schenk
patent: 6866850 (2005-03-01), Schenk
patent: 6870034 (2005-03-01), Breece et al.
patent: 6875434 (2005-04-01), Schenk
patent: 6890535 (2005-05-01), Schenk
patent: 6905686 (2005-06-01), Schenk
patent: 6913745 (2005-07-01), Schenk
patent: 6936246 (2005-08-01), Schenk
patent: 6946135 (2005-09-01), Schenk
patent: 6962707 (2005-11-01), Schenk
patent: 6972127 (2005-12-01), Schenk
patent: 6982084 (2006-01-01), Schenk
patent: 7014855 (2006-03-01), Schenk
patent: 7179892 (2007-02-01), Basi
patent: 7189819 (2007-03-01), Basi
patent: 7256273 (2007-08-01), Basi
patent: 7575880 (2009-08-01), Schenk et al.
patent: 7582733 (2009-09-01), Basi et al.
patent: 7588766 (2009-09-01), Schenk
patent: 7625560 (2009-12-01), Basi
patent: 7635473 (2009-12-01), Warne et al.
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: 2004/0043418 (2004-03-01), Holtzman et al.
patent: 2004/0081657 (2004-04-01), Schenk
patent: 2004/0082762 (2004-04-01), Basi et al.
patent: 2004/0087777 (2004-05-01), Basi et al.
patent: 2004/0192898 (2004-09-01), Jia et al.
patent: 2004/0229330 (2004-11-01), Bettencourt et al.
patent: 2005/0013815 (2005-01-01), Schenk
patent: 2005/0019330 (2005-01-01), Schenk
patent: 2005/0059802 (2005-03-01), Schenk et al.
patent: 2005/0090648 (2005-04-01), Tsurushita et al.
patent: 2005/0107594 (2005-05-01), Sun et al.
patent: 2005/0118651 (2005-06-01), Basi et al.
patent: 2005/0142131 (2005-06-01), Hinton et al.
patent: 2005/0169925 (2005-08-01), Bardroff et al.
patent: 2005/0249723 (2005-11-01), Lazar
patent: 2006/0029611 (2006-02-01), Schenk
patent: 2006/0034858 (2006-02-01), Schenk
patent: 2006/0099206 (2006-05-01), Sinacore et al.
patent: 2006/0194953 (2006-08-01), Bonnerjea et al.
patent: 2006/0198851 (2006-09-01), Basi
patent: 2006/0210557 (2006-09-01), Luisi et al.
patent: 2007/0072307 (2007-03-01), Godavarti et al.
patent: 2007/0082367 (2007-04-01), Godavarti et al.
patent: 2007/0134762 (2007-06-01), Arumugham et al.
patent: 2007/0154480 (2007-07-01), Schenk et al.
patent: 2007/0161088 (2007-07-01), Arumugham et al.
patent: 2008/0096818 (2008-04-01), Schenk et al.
patent: 2008/0145373 (2008-06-01), Arumugham
patent: 2008/0221306 (2008-09-01), Basi
patent: 2008/0227718 (2008-09-01), Schenk
patent: 2008/0279873 (2008-11-01), Seubert
patent: 2008/0292625 (2008-11-01), Schroeter
patent: 2008/0299074 (2008-12-01), Arumugham
patent: 2009/0069544 (2009-03-01), Basi
patent: 2009/0142270 (2009-06-01), Schroeter et al.
patent: 2009/0155256 (2009-06-01), Black et al.
patent: 2009/0191231 (2009-07-01), Schenk
patent: 2009/0285806 (2009-11-01), Sinacore et al.
patent: 2009/0297511 (2009-12-01), Schenk
patent: 0125023 (1984-11-01), None
patent: 0323027 (1989-07-01), None
patent: 1601697 (2005-12-01), None
patent: WO 87/02671 (1987-05-01), None
patent: WO 93/08829 (1993-05-01), None
patent: WO-01/62801 (2001-08-01), None
patent: WO-02/46237 (2002-06-01), None
patent: WO 02/46237 (2002-06-01), None
patent: WO-02/088306 (2002-11-01), None
patent: WO-02/088307 (2002-11-01), None
patent: WO-03/015691 (2003-02-01), None
patent: WO-03/016466 (2003-02-01), None
patent: WO-03/070760 (2003-08-01), None
patent: WO-03/077858 (2003-09-01), None
patent: WO-2004/080419 (2004-09-01), None
patent: WO-2004/108895 (2004-12-01), None
patent: WO-2006/066049 (2006-06-01), None
patent: WO-2006/066089 (2006-06-01), None
patent: WO-2006/066171 (2006-06-01), None
patent: WO 2006/138553 (2006-12-01), None
Definition of “chaotropism”. Stedman's Medical Dictionary 27thEdition, Lippincott Williams and Wilkins (2000).
Q Sepharose Product Instructions [online], [retrieved on Jun. 11, 2007] Retrieved from <http://www6.gelifesciences.com/aptrix/upp00919.nsf/Content/549194A30D280337C1256EB40044A91A/$file/71712800AE.pdf> Published Amersham Biosciences, 2002.
International Search Report for Application No. PCT/US2006/024026, dated Jun. 17, 2005.
Bales, K.R. et al, “Administration of an Anti-Aβ Fab Fragment to APPV717FTransgenic Mice Reduces Neuritic Plaque,”Therapeutics and Therapeutic Strategies, Poster Session P4-396, p. S587.
Bard, Frédérique et al, “Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology,”PNAS, vol. 100(4):2023-2028 (2003).
Bard, Frédérique et al, “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nature Medicine, vol. 6(8):916-919 (2000).
Bussière, Thierry et al, “Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive Aβ Immunotherapy on Their Clearance,”American Journal of Pathology, vol. 165(3):987-995 (2004).
Buttini, Manuel et al, “β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease,”The Journal of Neuroscience, vol. 25(40):9096-9101 (2005).
Chen, Guiquan et al, “A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease,”Nature, vol. 408:975-979 (2000).
Eliasson, Margareta et al, “Chimeric IgG-binding Receptors Engineered from Staphylococcal Protein A and Streptococcal Protein G,”The Journal of Biological Chemistry, vol. 263(9):4323-4327 (1988).
Games, Dora et al, “Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with Aβ1-42,”Ann. NY Acad. Sci., vol. 920:274-284 (2000).
Hardy, John, “Amyloid, the presenilins and Alzheimer's disease,”Trends Neurosci., vol. 20:154-159 (1997).
Harris, Reed J., “Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture,”Journal of Chromatography A, vol. 705:129-134 (1995).
Johnson-Wood, K. et al, “Amyloid precursor protein processing and Aβ42deposition in a transgenic mouse model of Alzheimer's disease, ”Proc. Natl. Acad. Sci. USA, vol. 94:1550-1555 (1997).
Kajkowski, Eileen M. et al, “β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation M
Godavarti Ranganathan
Iskra Timothy
Alston & Bird LLP
Janssen Alzheimer Immunotherapy
Saunders David A
Wyeth LLC
LandOfFree
Methods of purifying anti A β antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of purifying anti A β antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of purifying anti A β antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4250705